48 related articles for article (PubMed ID: 38566053)
21. Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma.
Yoon SE; Kim YJ; Shim JH; Park D; Cho J; Ko YH; Park WY; Mun YC; Lee KE; Cho D; Kim WS; Kim SJ
Cancer Res Treat; 2022 Apr; 54(2):597-612. PubMed ID: 34325497
[TBL] [Abstract][Full Text] [Related]
22. Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study.
Rivas-Delgado A; Nadeu F; Enjuanes A; Casanueva-Eliceiry S; Mozas P; Magnano L; Castrejón de Anta N; Rovira J; Dlouhy I; Martín S; Osuna M; Rodríguez S; Simó M; Pinyol M; Baumann T; Beà S; Balagué O; Delgado J; Villamor N; Setoain X; Campo E; Giné E; López-Guillermo A
Clin Cancer Res; 2021 Jan; 27(2):513-521. PubMed ID: 33122345
[TBL] [Abstract][Full Text] [Related]
23. Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy.
Montesinos-Rongen M; Brunn A; Tuchscherer A; Borchmann P; Schorb E; Kasenda B; Altmüller J; Illerhaus G; Ruge MI; Maarouf M; Büttner R; Hansmann ML; Hallek M; Prinz M; Siebert R; Deckert M
J Mol Diagn; 2020 Oct; 22(10):1300-1307. PubMed ID: 32745612
[TBL] [Abstract][Full Text] [Related]
24. Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas.
Bobillo S; Crespo M; Escudero L; Mayor R; Raheja P; Carpio C; Rubio-Perez C; Tazón-Vega B; Palacio C; Carabia J; Jiménez I; Nieto JC; Montoro J; Martínez-Ricarte F; Castellvi J; Simó M; Puigdefàbregas L; Abrisqueta P; Bosch F; Seoane J
Haematologica; 2021 Feb; 106(2):513-521. PubMed ID: 32079701
[TBL] [Abstract][Full Text] [Related]
25. Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis.
King RL; Goodlad JR; Calaminici M; Dotlic S; Montes-Moreno S; Oschlies I; Ponzoni M; Traverse-Glehen A; Ott G; Ferry JA
Virchows Arch; 2020 May; 476(5):647-665. PubMed ID: 31863183
[TBL] [Abstract][Full Text] [Related]
26. The OncoLifeS data-biobank for oncology: a comprehensive repository of clinical data, biological samples, and the patient's perspective.
Sidorenkov G; Nagel J; Meijer C; Duker JJ; Groen HJM; Halmos GB; Oonk MHM; Oostergo RJ; van der Vegt B; Witjes MJH; Nijland M; Havenga K; Maduro JH; Gietema JA; de Bock GH
J Transl Med; 2019 Nov; 17(1):374. PubMed ID: 31727094
[TBL] [Abstract][Full Text] [Related]
27. MYD88 in the driver's seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications.
de Groen RAL; Schrader AMR; Kersten MJ; Pals ST; Vermaat JSP
Haematologica; 2019 Dec; 104(12):2337-2348. PubMed ID: 31699794
[TBL] [Abstract][Full Text] [Related]
28. The emerging role of cell-free DNA as a molecular marker for cancer management.
Bronkhorst AJ; Ungerer V; Holdenrieder S
Biomol Detect Quantif; 2019 Mar; 17():100087. PubMed ID: 30923679
[TBL] [Abstract][Full Text] [Related]
29. Tumor cell-free DNA detection in CSF for primary CNS lymphoma diagnosis.
Rimelen V; Ahle G; Pencreach E; Zinniger N; Debliquis A; Zalmaï L; Harzallah I; Hurstel R; Alamome I; Lamy F; Voirin J; Drénou B
Acta Neuropathol Commun; 2019 Mar; 7(1):43. PubMed ID: 30885253
[No Abstract] [Full Text] [Related]
30. Primary CNS Lymphomas: Challenges in Diagnosis and Monitoring.
Chiavazza C; Pellerino A; Ferrio F; Cistaro A; Soffietti R; Rudà R
Biomed Res Int; 2018; 2018():3606970. PubMed ID: 30035121
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma.
Hattori K; Sakata-Yanagimoto M; Suehara Y; Yokoyama Y; Kato T; Kurita N; Nishikii H; Obara N; Takano S; Ishikawa E; Matsumura A; Hasegawa Y; Chiba S
Cancer Sci; 2018 Jan; 109(1):225-230. PubMed ID: 29151258
[TBL] [Abstract][Full Text] [Related]
32. Primary CNS Lymphoma.
Grommes C; DeAngelis LM
J Clin Oncol; 2017 Jul; 35(21):2410-2418. PubMed ID: 28640701
[TBL] [Abstract][Full Text] [Related]
33. Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma.
Fontanilles M; Marguet F; Bohers É; Viailly PJ; Dubois S; Bertrand P; Camus V; Mareschal S; Ruminy P; Maingonnat C; Lepretre S; Veresezan EL; Derrey S; Tilly H; Picquenot JM; Laquerrière A; Jardin F
Oncotarget; 2017 Jul; 8(29):48157-48168. PubMed ID: 28636991
[TBL] [Abstract][Full Text] [Related]
34. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly.
Zink F; Stacey SN; Norddahl GL; Frigge ML; Magnusson OT; Jonsdottir I; Thorgeirsson TE; Sigurdsson A; Gudjonsson SA; Gudmundsson J; Jonasson JG; Tryggvadottir L; Jonsson T; Helgason A; Gylfason A; Sulem P; Rafnar T; Thorsteinsdottir U; Gudbjartsson DF; Masson G; Kong A; Stefansson K
Blood; 2017 Aug; 130(6):742-752. PubMed ID: 28483762
[TBL] [Abstract][Full Text] [Related]
35. Accuracy of flow cytometry and cytomorphology for the diagnosis of meningeal involvement in lymphoid neoplasms: A systematic review.
Canovi S; Campioli D
Diagn Cytopathol; 2016 Oct; 44(10):841-56. PubMed ID: 27458077
[TBL] [Abstract][Full Text] [Related]
36. Targetable genetic features of primary testicular and primary central nervous system lymphomas.
Chapuy B; Roemer MG; Stewart C; Tan Y; Abo RP; Zhang L; Dunford AJ; Meredith DM; Thorner AR; Jordanova ES; Liu G; Feuerhake F; Ducar MD; Illerhaus G; Gusenleitner D; Linden EA; Sun HH; Homer H; Aono M; Pinkus GS; Ligon AH; Ligon KL; Ferry JA; Freeman GJ; van Hummelen P; Golub TR; Getz G; Rodig SJ; de Jong D; Monti S; Shipp MA
Blood; 2016 Feb; 127(7):869-81. PubMed ID: 26702065
[TBL] [Abstract][Full Text] [Related]
37. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.
Genovese G; Kähler AK; Handsaker RE; Lindberg J; Rose SA; Bakhoum SF; Chambert K; Mick E; Neale BM; Fromer M; Purcell SM; Svantesson O; Landén M; Höglund M; Lehmann S; Gabriel SB; Moran JL; Lander ES; Sullivan PF; Sklar P; Grönberg H; Hultman CM; McCarroll SA
N Engl J Med; 2014 Dec; 371(26):2477-87. PubMed ID: 25426838
[TBL] [Abstract][Full Text] [Related]
38. Age-related clonal hematopoiesis associated with adverse outcomes.
Jaiswal S; Fontanillas P; Flannick J; Manning A; Grauman PV; Mar BG; Lindsley RC; Mermel CH; Burtt N; Chavez A; Higgins JM; Moltchanov V; Kuo FC; Kluk MJ; Henderson B; Kinnunen L; Koistinen HA; Ladenvall C; Getz G; Correa A; Banahan BF; Gabriel S; Kathiresan S; Stringham HM; McCarthy MI; Boehnke M; Tuomilehto J; Haiman C; Groop L; Atzmon G; Wilson JG; Neuberg D; Altshuler D; Ebert BL
N Engl J Med; 2014 Dec; 371(26):2488-98. PubMed ID: 25426837
[TBL] [Abstract][Full Text] [Related]
39. High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites.
Kraan W; Horlings HM; van Keimpema M; Schilder-Tol EJ; Oud ME; Scheepstra C; Kluin PM; Kersten MJ; Spaargaren M; Pals ST
Blood Cancer J; 2013 Sep; 3(9):e139. PubMed ID: 24013661
[TBL] [Abstract][Full Text] [Related]
40. Detection of circulating tumor DNA in plasma of patients with primary CNS lymphoma by digital droplet PCR.
Zhong Y; Tan GW; Bult J; Veltmaat N; Plattel W; Kluiver J; Enting R; Diepstra A; van den Berg A; Nijland M
BMC Cancer; 2024 Apr; 24(1):407. PubMed ID: 38566053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
